Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Apotex Imiquimod 5% Cream vs Aldara in Actinic Keratosis
NCT00859105Phase 3Completed
- Sponsor
- Apotex Inc.
- Start
- Feb 2008
- Primary completion
- Nov 2008
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of imiquimod in actinic keratosis (AK), sponsored by Apotex Inc.. Started Feb 2008; status: completed.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT00859105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00859105.